MPLNET.com » Test Menu » Trisomy 8 by FISH Client Login | Email | Phone: 1.800.932.2943

Trisomy 8 by FISH

Test Code

F T8

Test Synonyms

+8, CEP 8

Associations

Acute myeloid leukemia (AML), Chronic myelogenous leukemia (CML), Myelodysplastic syndrome (MDS)

Methodology

Fluorescence in situ Hybridization (FISH)

Turnaround Time

3-5 days

Specimen Requirements

2.0 mL (min. 1.0 mL) peripheral blood in sodium heparin preferred, EDTA accepted
1.0 mL (min. 0.5 mL) bone marrow in sodium heparin preferred, EDTA accepted
5 mm^3 fresh tissue or 3.0 mL (min. 2.0 mL) FNA in MPLN RPMI media

Specimen Stability
Peripheral blood and bone marrow stable at 18-25°C for 72 hours
Fresh tissue or FNA stable at 2-8°C for 72 hours
Storage & Handling

Whole blood and bone marrow, ship ambient
Fresh tissue or FNA ship in a Styrofoam container with a cool/refrigerated pack (Do not allow cool pack to directly contact sample)

Causes for Rejection

Clotted specimen; Specimen exposed to extreme temperature; Anticoagulant toxic to cells; Insufficient number of cells

Reference Range

Normal cells have two aqua signals. Abnormal cells containing trisomy 8, have a three aqua signal pattern.

Description

Trisomy 8 is relatively specific for myeloid disorders and is rarely observed in lymphoid disease. It is found in 10-15% of patients with acute myeloid leukemia (AML), 15-20% of patients with myelodysplastic syndromes (MDS), as a secondary abnormality in Philadelphia chromosome positive CML, and in other myeloproliferative disorders. Trisomy 8 occurs as the sole chromosome abnormality in about 40% of AML cases, occurs in combination with simple chromosome changes in 35% of cases, and as part of a complex karyotype in 25% of AML patients.

References
  1. Matsuoka H et al. (2005). Establishment of a human myeloid cell line with trisomy 8 derived from overt leukemia following myelodysplastic syndrome.
  2. Wolman SR. (2002). Impact of trisomy 8 (+8) on clinical presentation, treatment response, and survival in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 100(1):29.
  3. Huret JL.(November 1998) +8 or trisomy 8. Atlas Genet Cytogenet Oncol Haematol.